Zhuhai Rundu Pharmaceutical Co Ltd Class A

Zhuhai Rundu Pharmaceutical Co., Ltd. announced that its amlodipine besylate active pharmaceutical ingredient has recently received marketing approval from the National Medical Products Administration, with registration number Y20240001262. The API is used for the treatment of hypertension and angina pectoris. The company submitted its registration application in January 2025, received a supplementary study notice in November 2025, completed the supplementary study and submitted the materials in March 2026, and obtained approval in August 2026. The company stated that this approval will improve its product portfolio in the cardiovascular and cerebrovascular treatment field, enrich its product matrix, and help enhance market competitiveness, while also noting that future sales may be subject to uncertainty due to policy and market changes.

Rundu Shares released its 2026 interim report, with net profit attributable to the parent company of 40.751 million yuan, an increase of 76.9441 million yuan compared with the same period last year, achieving a turnaround from loss to profit. The company's total operating revenue was 709 million yuan, up 29.34 percent year on year. Net cash inflow from operating activities was 72.7134 million yuan, up 669.59 percent year on year. The company's latest asset-liability ratio was 46.71 percent, gross margin was 43.87 percent, return on equity was 3.78 percent, and diluted earnings per share was 0.12 yuan.

Rundu Shares announced that its global first-in-class drug, Higenamine Hydrochloride Injection, has been selected for the third batch of the Guangdong Province approved innovative drug and device product catalog. The drug is a chemical class 1 product, indicated for radionuclide myocardial perfusion imaging to assess myocardial ischemia. This selection reflects the authorities' recognition of the product's technological innovation, clinical value, and industrialization capability. Products included in the catalog will enjoy a series of supportive policies from Guangdong Province to promote the development of innovative drugs and devices, which will benefit the clinical promotion and market sales of the company's innovative drug products within the province and have a positive impact on the company's long-term development.

On the evening of July 12, multiple listed companies on the Shanghai and Shenzhen exchanges released important announcements. StarNeto clarified that its satellite communication business is unrelated to the breakthrough in sea recovery technology for the Long March 10B carrier rocket, and that revenue from new businesses such as the low-altitude economy accounts for less than 5%. Zhezhong Co., Ltd. cautioned that there is uncertainty in converting new orders signed in 2026 into revenue, and that revenue from its main business of complete switchgear has continued to decline. Juli Sling was fined 4.5 million yuan by the Hebei Securities Regulatory Bureau for misleading statements on an interactive platform. The controlling shareholder of Western Region Gold, Xinjiang Nonferrous Metals, plans to merge entirely with Xinjiang Geology and Mining Investment Group, with the actual controller remaining unchanged. In terms of earnings, Yuehai Feed's net profit for the first half of the year is expected to increase by 965.92% to 1302.52%, Ningbo Fubon is expected to increase by 416.54% to 519.85%, Shanshan Co., Ltd. is expected to increase by 262% to 334%, Sanyou Chemical is expected to increase by about 129%, Yalian Machinery's flash report shows net profit growth of 60.06%, Shengnuo Bio is expected to increase by 43.23% to 64.79%, and both Rundu Pharma and China Satellite are expected to turn losses into profits year-on-year. In addition, Taikang Life Insurance plans to reduce its stake in Guoke Hengtai by no more than 3%, and Hengtong Co., Ltd. plans to invest in a digital smart industrial park in Indonesia, with a planned investment of no more than 2 billion yuan.

Rundu Shares announced that the company recently received two Drug Registration Certificates for Azilsartan Medoxomil Potassium Tablets issued by the National Medical Products Administration. The drug is indicated for the treatment of essential hypertension in adults. This approval further improves the company's product layout in the cardiovascular and cerebrovascular treatment field, promotes the formation of a vertically integrated industrial chain from active pharmaceutical ingredients to finished formulations, and helps enhance market competitiveness.

On the evening of July 12, several A-share listed companies disclosed earnings forecasts, sharply raising their first-half performance estimates. Ningbo Fubang expects net profit of 50 million to 60 million yuan, up 416.54% to 519.85% year-on-year, with its core business having shifted to the production and sale of electrical contact materials. Shanshan Co. expects net profit of 750 million to 900 million yuan, up 262% to 334% year-on-year, with its two main businesses, anode materials and polarizer operations, together expected to achieve net profit of 880 million to 950 million yuan. Yuehai Feed expects net profit of 38 million to 50 million yuan, up 965.92% to 1,302.52% year-on-year. In addition, Sanyou Chemical's net profit is expected to rise about 129% year-on-year, Shengnuo Bio's net profit is expected to rise 43.23% to 64.79% year-on-year, and both China Satellite and Rundu Pharma expect to turn losses into profits year-on-year. Yalian Machinery disclosed a performance flash report, with first-half revenue of 515 million yuan, up 36.93% year-on-year, and net profit of 157 million yuan, up 60.06% year-on-year.

Rundu Pharma issued an announcement, expecting net profit attributable to the parent for the first half of 2026 to be between 35 million yuan and 42 million yuan, a year-on-year increase of 196.70% to 216.04%. Net profit after deducting non-recurring items is expected to be between 28 million yuan and 34 million yuan, a year-on-year increase of 162.43% to 175.81%. Basic earnings per share are expected to be between 0.10 yuan and 0.12 yuan, compared with negative 0.11 yuan in the same period last year. The performance growth is mainly due to the company actively expanding domestic and international markets, increased sales volume of active pharmaceutical ingredients and formulation products, as well as improved capacity utilization and expanded production scale at its subsidiary Jingmen Company, which drove down costs and led to significant growth in sales revenue and gross profit.